Sodium Sulfacetamide 8% Sulfur 4% Topical Suspension

Manufacturer
Oncor Pharmaceuticals
Effective date
2026-03-22
Label type
HUMAN PRESCRIPTION DRUG LABEL
Version
5
Source
full-release
Hydrated at
2026-05-31 22:10:51

Label at a glance#

ProductSodium Sulfacetamide 8% Sulfur 4% CLEANSER
Active ingredientSULFACETAMIDE SODIUM, SULFUR
Label structure20 sections

Dosage and administration

Apply Sodium Sulfacetamide 8% and Sulfur 4% Topical Suspension once or twice daily to affected areas, or as directed by your physician. Wet skin and liberally apply to areas to be cleansed. Massage gently into skin for 10-20 seconds, working into a full lather, rinse thoroughly and pat dry. If drying occurs, it may be controlled by rinsing off Sodium Sulfacetamide 8% and Sulfur 4% Topical Suspension sooner or usin...

Storage and handling

Store at 20 o C to 25 o C ( 68 o F to 77 o F ), excursions permitted between 15 o C and 30 o C (between 59 o F and 86 o F ). Brief exposure to temperatures up to 40°C (104 o F) may be tolerated provided the mean kinetic temperature does not exceed 25 o C (77 o F) however, such exposure should be minimized. Protect from freezing.

Label contents#

Full prescribing information#

SPL UNCLASSIFIED SECTION

In A Vehical Containing Green Tea And Aloe
Rx Only

DESCRIPTION

DESCRIPTION SECTION

Each gram of Sodium Sulfacetamide 8% and Sulfur 4% Topical Suspension contains 80 mg of sodium sulfacetamide and 40 mg of sulfur in a formulation containing Aloe vera leaf extract, Butylated hydroxytoluene, Cetyl alcohol, Citric acid, Cocamidopropyl betaine, Disodium EDTA, Glycerin, Glyceryl stearate SE, Green tea extract, PEG-100 stearate, Phenoxyethanol, Purified water, Sodium laureth sulfate, Sodium thiosulfate, Stearyl alcohol, Triacetin, Xanthan gum.

Sodium sulfacetamide is a sulfonamide with antibacterial activity while sulfur acts as a keratolytic agent. Chemica ly sodium sulfacetamide is N-[(4-aminophenyl) sulfonyl]-acetamide, monosodium salt, monohydrate. The structural formula is:

structurestructure

INDICATIONS

INDICATIONS & USAGE SECTION

Sodium Sulfacetamide 8% and Sulfur 4% Topical Suspension is indicated in the topical control of acne vulgaris, acne rosacea and seborrheic dermatitis.

INSTRUCTIONS FOR USE SECTION

FOR EXTERNAL USE ONLY. NOT FOR OPHTHALMIC USE.
Keep out of reach of children. Keep container tightly closed.
Shake well before use.

OTHER SAFETY INFORMATION

In case of accidental ingestion contact a Poison Control Center immediately. Keep container tightly closed.

You may report side effects by ca ling Oncor Pharmaceuticals (9 a.m. to 5 p.m. EST), at 1-443-876-7600 or FDA at 1-800-FDA-1088.

PRECAUTIONS SECTION

Incase of itching or redness discontinue the use.

STORAGE

STORAGE AND HANDLING SECTION

Store at 20 oC to 25 oC ( 68 oF to 77 oF ), excursions permitted between 15 oC and 30 oC (between 59 oF and 86 oF ). Brief exposure to temperatures up to 40°C (104 oF) may be tolerated provided the mean kinetic temperature does not exceed 25 oC (77 oF) however, such exposure should be minimized.

Protect from freezing.

DOSAGE AND ADMINISTRATION

DOSAGE & ADMINISTRATION SECTION

Apply Sodium Sulfacetamide 8% and Sulfur 4% Topical Suspension once or twice daily to affected areas, or as directed by your physician. Wet skin and liberally apply to areas to be cleansed. Massage gently into skin for 10-20 seconds, working into a full lather, rinse thoroughly and pat dry. If drying occurs, it may be controlled by rinsing off Sodium Sulfacetamide 8% and Sulfur 4% Topical Suspension sooner or using less often.

CONTRAINDICATIONS

CONTRAINDICATIONS SECTION

This product is contraindicated for use by persons with known or suspected hypersensitivity to sulfonamides, sulfur or any other component of this preparation. This product is not to be used by patients with kidney disease.

CLINICAL PHARMACOLOGY

CLINICAL PHARMACOLOGY SECTION

The most widely accepted mechanism of action of sulfonamides is the woods fildes theory, which is based on the fact that sulfonamides act as competitive antagonists to para-aminobenzoic acid (PABA), an essential component for bacterial growth. While absorption through intact skin has not been determined, sodium sulfacetamide is readily absorbed from the gastrointestinal tract when taken orally and excreted in the urine, largely unchanged. The biological half-life has variously been reported as 7 to 12.8 hours. The exact mode of action of sulfur in the treatment of acne is not known, but it has been reported that it inhibits the growth of Propionibacterium acnes and the formation of free fatty acids.

WARNINGS

WARNINGS SECTION

Although rare, sensitivity to sodium sulfacetamide may occur. Therefore, caution and careful supervision should be observed when prescribing this drug for patients who may be prone to hypersensitivity to topical sulfonamides. Systemic toxic reactions such as agranulocytosis, acute hemolytic anemia, purpura hemorrhagica, drug fever, jaundice and contact dermatitis indicate hypersensitivity to sulfonamides. Particular caution should be employed if areas of denuded or abraded skin are involved.

PRECAUTIONSGENERAL

GENERAL PRECAUTIONS SECTION

If irritation develops, use of the product should be discontinued and appropriate therapy instituted. Patients should be carefully observed for possible local irritation or sensitization during long-term therapy. The object of this therapy is to achieve desquamation without irritation, but sodium sulfacetamide and sulfur can cause reddening and scaling of the epidermis. These side effects are not unusual in the treatment of acne vulgaris, but patients should be cautioned about the possibility.

INFORMATION FOR PATIENTS

INFORMATION FOR PATIENTS SECTION

Avoid contact with eyes, eyelids, lips and mucous membranes. If accidental contact occurs, rinse with water. If excessive irritation develops, discontinue use and consult your physician.

CARCINOGENESIS, MUTAGENESIS AND IMPAIRMENT OF FERTILITY

CARCINOGENESIS & MUTAGENESIS & IMPAIRMENT OF FERTILITY SECTION

Long-term studies in animals have not been performed to evaluate carcinogenic potential.

PREGNANCYCategory C

PREGNANCY SECTION

Animal reproduction studies have not been conducted with Sodium Sulfacetamide 8% and Sulfur 4% Topical Suspension. It is not known whether
Sodium Sulfacetamide 8% and Sulfur 4% Topical Suspension can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Sodium Sulfacetamide 8% and Sulfur 4% Topical Suspension should be given to a pregnant woman only if clearly needed.

NURSING MOTHERS

NURSING MOTHERS SECTION

It is not known whether sodium sulfacetamide is excreted in the human milk following topical use of Sodium Sulfacetamide 8% and Sulfur 4% Topical Suspension. However, small amounts of orally administered sulfonamides have been reported to be eliminated in human milk. In view of this and because many drugs are excreted in human milk, caution should be exercised when Sodium Sulfacetamide 8% and Sulfur 4% Topical Suspension is administered to a nursing woman.

PEDIATRIC USE

PEDIATRIC USE SECTION

Safety and effectiveness in children under the age of 12 have not been established.

ADVERSE REACTIONS

ADVERSE REACTIONS SECTION

Although rare, sodium sulfacetamide may cause local irritation. Call your doctor for medical advice about side effects.

HOW SUPPLIED

HOW SUPPLIED SECTION

Sodium Sulfacetamide 8% and Sulfur 4% Topical Suspension is available in
10 fl oz (296 mL) bottles NDC 83720-542-10.

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

Manufactured In USA For :

Oncor Pharmaceuticals
6755 Business Pkwy Suite 202
Elkridge, MD 21075
United States.
Rev. 08/25

sss 8-4 topical suspension 10 ozsss 8-4 topical suspension 10 oz

sss 8-4 topical suspension 16 ozsss 8-4 topical suspension 16 oz

DailyMed RxNorm Mappings#

RxCUI, RxNorm string, TTY table
RxCUIRxNorm stringTTYSPL version
1010234sulfacetamide sodium 8 % / sulfur 4 % Medicated Liquid SoapPSN5
1010234sulfacetamide sodium 80 MG/ML / sulfur 40 MG/ML Medicated Liquid SoapSCD5
1010234sulfacetamide sodium 8 % / sulfur 4 % Medicated Liquid SoapSY5
1010234sulfacetamide sodium 8 % / sulfur 4 % Topical SuspensionSY5

DailyMed Pharmacologic Classes#

Class, Version, Type table
ClassVersionTypeEffective
SULFACETAMIDE Pharmacologic Class Indexing2Indexing - Pharmacologic Class20180813

Product Linked Resources#

Resource, Code type, Value table
ResourceCode typeValueEquivalent identifiersSource image
BarcodeEAN-130383720542105GTIN-13: 0383720542105
EAN-13: 0383720542105
GTIN-12: 383720542105
UPC-A: 383720542105
GTIN storage (14 digits): 00383720542105
sss 8-4 topical suspension 10 oz.jpg
BarcodeEAN-130383720542167GTIN-13: 0383720542167
EAN-13: 0383720542167
GTIN-12: 383720542167
UPC-A: 383720542167
GTIN storage (14 digits): 00383720542167
sss 8-4 topical suspension 16 oz.jpg

DailyMed Product Concepts#

Product concept, Relation, Version table
Product conceptRelationVersionEffective
4073022c-5d5d-48f5-82ed-091ad146a4b2Product name120171211
9ffbd0ae-0bce-c086-b707-f0da5f8cd7c5Product name120150828
0304b7d2-7a07-d53b-750f-36012ae6612eProduct name120140508
64c0cc7e-6478-3ca1-8cd7-9a1251d5a3f6Product name120140508
9ae74339-0a3d-82e9-5dd1-88bd2607bd6bProduct name120140508
e44e38a9-2d9e-b0e2-cce9-490554639f3dProduct name120140508

DailyMed Package Descriptions#

Package NDC, Product, Description table
Package NDCProductDescriptionFormQuantityStrengthSPL version
83720-542-16Sodium Sulfacetamide 8% Sulfur 4% CLEANSER473 mL in 1 BOTTLE, PLASTICLIQUID4735

DailyMed Billing Units#

Package NDC, Billing unit, Product NDC table
Package NDCBilling unitProduct NDCDailyMed indexing SPLSPL versionEffective
83720-542-10ML - Milliliter83720-542d9e31e32-f4f8-4bf0-819b-8004180e672212025-09-12
83720-542-16ML - Milliliter83720-542967852a2-28d0-4aa7-9527-adc65ba7559812025-11-13

Products#

Every source-derived product name is available through these pages.

DailyMed product names page 1 of 1 · 22 matching rows.

NDC Codes#

Product NDC, Package NDC table
Product NDCPackage NDC
83720-54283720-542-16

Ingredients#

Every source-derived ingredient row is available through these pages.

DailyMed ingredient rows page 1 of 1 · 19 matching rows.

Source Document#

Source XML

Older Hydrated Versions#

Version, Effective date, Source table
VersionEffective dateSourceHydrated
42026-02-11monthly-update2026-06-03 17:57:29
32025-10-18monthly-update2026-06-03 17:41:53
22025-08-26full-release2026-05-31 21:41:15

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 1 matching rows.

Brand, Generic, Manufacturer table
BrandGenericManufacturerSPL set IDEffective dateAvailable safety fieldsJoin
Sodium Sulfacetamide 8% Sulfur 4% CLEANSERSODIUM SULFACETAMIDE AND SULFUROncor Pharmaceuticalsd44a7a26-ea6b-469f-931a-812a031868ea2026-03-22Warnings, Adverse reactionsExact identifier
ndc (package): 83720-542-16
ndc (product): 83720-542
ndc11 (package): 83720054216
spl id: 4da2e69d-d777-91cb-e063-6294a90acda5
spl set id: d44a7a26-ea6b-469f-931a-812a031868ea

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.